Artiva Biotherapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ARTV | NKTX | ACRS | CHRS | IPHA | CRVS | |
|---|---|---|---|---|---|---|
| Market cap | 206.32M | 123.91M | 570.34M | 131.36M | 159.17M | 889.16M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -2.1 | -1.0 | -5.1 | -1.3 | -3.0 | -9.9 |
| Price/book | 0.6 | 0.5 | 4.1 | 2.2 | -2.9 | 3.9 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +22.67% | −12.18% | +62.11% | −42.95% | −20.83% | +35.17% |
| Today | +0.48% | +13.07% | −1.60% | +5.54% | +5.56% | +7.53% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All ARTV news ›Artiva Biotherapeutics downgraded to Neutral at Wedbush after patient death
Wedbush analyst David Nierengarten downgraded Artiva Biotherapeutics (ARTV) to Neutral from Outperform with a price target of $4, down from $40.... Artiva Biotherapeutics downgraded to Neutral at Wedbush after patient death Wedbush analyst…
Artiva Biotherapeutics (NASDAQ:ARTV) Stock Rating Cut to Sell at Wall Street Zen
Posted by Tristan Rich on Nov 1st, 2026 Wall Street Zen cut shares of Artiva Biotherapeutics (NASDAQ:ARTV – Free Report) from a hold rating to a sell rating in a research report report published on Saturday morning,Wall Street Zen reports.…
Artiva Biotherapeutics Cuts 94% of Staff in San Diego
Artiva Biotherapeutics is abandoning its lead experimental cell therapy and slashing roughly 94% of its workforce after two patients died during a clinical trial testing the treatment for autoimmune disease. The San Diego-based company,…
After 2 patient deaths and cell therapy durability concerns, Artiva cuts 94% of workforce
BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe.…
More from 1 other outlet
Artiva to quit autoimmune cell therapy work, cut staff after patient deaths
The disclosure makes Artiva the third company to recently report fatal events in an autoimmune cell therapy trial, following announcements from Novartis and Bristol Myers Squibb. Artiva Biotherapeutics will lay off most of its staff and…
Artiva Biotherapeutics (NASDAQ:ARTV) Stock Dropped to “Hold” by Needham & Company LLC
Posted by Defense World Staff on Oct 28th, 2026 Needham & Company LLC cut shares of Artiva Biotherapeutics (NASDAQ:ARTV – Free Report) from a buy rating to a hold rating in a report published on Tuesday morning, Marketbeat.com reports.…
Artiva slumps after discontinuing lead asset
Artiva Biotherapeutics (ARTV) stock plunged after fatal trial events prompted the company to discontnue its lead canddiate AlloNK and layoff staff. Read more here. Artiva Biotherapeutics (ARTV) lost more than 30% in premarket trading on…
Artiva Biotherapeutics Reducing its Workforce by Approximately 94%
Artiva Biotherapeutics, Inc. announced in connection with the discontinuation of AlloNK development and to preserve capital while evaluating strategic alternatives, Artiva is reducing its workforce by... Published on 10/27/2026 at 03:55 pm…
Artiva Axes 94% of Workforce, Weighs Strategic Alternatives After Two Patients in Phase IIa Trial Die
NK cell therapy developer halts development of lead candidate AlloNK®, being assessed with rituximab in rheumatoid arthritis (RA) and other B-cell-driven autoimmune diseases Artiva Biotherapeutics said it will eviscerate its workforce 94%…
Financial Review: Artiva Biotherapeutics (NASDAQ:ARTV) and Taysha Gene Therapies (NASDAQ:TSHA)
Posted by Michael Walen on Oct 11th, 2026 Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) and Artiva Biotherapeutics (NASDAQ:ARTV – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- stocktitan.net5
- themarketsdaily.com2
- biopharmadive.com1
- biospace.com1
- defenseworld.net1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 17 articles, not a forecast.